These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
195 related items for PubMed ID: 26671072
1. BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis. Chen Y, Sadow PM, Suh H, Lee KE, Choi JY, Suh YJ, Wang TS, Lubitz CC. Thyroid; 2016 Feb; 26(2):248-55. PubMed ID: 26671072 [Abstract] [Full Text] [Related]
3. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature. Krishnamurthy A, Ramshankar V, Murherkar K, Vidyarani S, Raghunandhan GC, Das A, Desai PB, Albert K. Indian J Cancer; 2017 Feb; 54(1):372-378. PubMed ID: 29199726 [Abstract] [Full Text] [Related]
4. BRAFV600E mutation does not predict lymph node metastases and recurrence in Chinese papillary thyroid microcarcinoma patients. Zhao H, Liu CH, Lu Y, Liu SZ, Yeerkenbieke P, Cao Y, Xia Y, Gao LY, Liu YW, Liu ZW, Chen SG, Liang ZY, Li XY. Oral Oncol; 2024 May; 152():106755. PubMed ID: 38547780 [Abstract] [Full Text] [Related]
6. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, Zhang Y, Cheng W, Zhao W. Ann Surg Oncol; 2009 Feb; 16(2):240-5. PubMed ID: 19034577 [Abstract] [Full Text] [Related]
11. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors. Choi SY, Park H, Kang MK, Lee DK, Lee KD, Lee HS, Kim SW, Lee EN, Hong JC. World J Surg Oncol; 2013 Nov 14; 11():291. PubMed ID: 24228637 [Abstract] [Full Text] [Related]
12. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ, Qu JM. Ann Surg Oncol; 2010 Dec 14; 17(12):3294-300. PubMed ID: 20953721 [Abstract] [Full Text] [Related]
13. The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome? Walczyk A, Kowalska A, Kowalik A, Sygut J, Wypiórkiewicz E, Chodurska R, Pięciak L, Góźdź S. Clin Endocrinol (Oxf); 2014 Jun 14; 80(6):899-904. PubMed ID: 24354346 [Abstract] [Full Text] [Related]
14. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. Liu C, Chen T, Liu Z. World J Surg Oncol; 2016 Sep 06; 14(1):241. PubMed ID: 27600854 [Abstract] [Full Text] [Related]
19. BRAF V600E mutation in papillary thyroid microcarcinoma: is it a predictor for the prognosis of patients with intermediate to high recurrence risk? Cao J, Chen B, Zhu X, Sun Y, Li X, Zhang W, Wang X. Endocrine; 2024 Apr 06; 84(1):160-170. PubMed ID: 37851243 [Abstract] [Full Text] [Related]
20. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK. Clin Endocrinol (Oxf); 2006 Sep 06; 65(3):364-8. PubMed ID: 16918957 [Abstract] [Full Text] [Related] Page: [Next] [New Search]